BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,343 | -67.3% | 331 | -67.5% | 0.00% | -100.0% |
| Q2 2023 | $7,160 | +224.0% | 1,017 | +283.8% | 0.00% | – |
| Q1 2023 | $2,210 | -10.9% | 265 | +22.7% | 0.00% | – |
| Q4 2022 | $2,480 | +24.0% | 216 | +54.3% | 0.00% | – |
| Q3 2022 | $2,000 | 0.0% | 140 | -35.8% | 0.00% | – |
| Q2 2022 | $2,000 | -50.0% | 218 | -3.5% | 0.00% | -100.0% |
| Q1 2022 | $4,000 | – | 226 | -8.9% | 0.00% | – |
| Q1 2020 | $0 | – | 248 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |